Results 281 to 290 of about 27,856 (310)
Some of the next articles are maybe not open access.
Treatment Options for Tauopathies
Current Treatment Options in Neurology, 2012To date, there are no approved and established pharmacologic treatment options for tauopathies, a very heterogenous group of neuropsychiatric diseases often leading to dementia and clinically diagnosed as atypical Parkinson syndromes. Among these so-called Parkinson plus syndromes are progressive supranuclear palsy (PSP), also referred to as Steele ...
Tarik, Karakaya +3 more
openaire +2 more sources
Pathogenesis of the Tauopathies
Journal of Molecular Neuroscience, 2011Microtubule-associated protein tau is the most commonly misfolded protein in human neurodegenerative diseases, where it becomes hyperphosphorylated and filamentous. Mutations in MAPT, the tau gene, cause approximately 5% of cases of frontotemporal dementia. They are frequently accompanied by parkinsonism. The existence of MAPT mutations has established
Michel, Goedert +1 more
openaire +2 more sources
Neuropathology of familial tauopathy
Neuropathology, 2006Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP‐17) is a hereditary progressive neurodegenerative disorder. FTDP‐17 was originally defined in Ann Arbor, Michigan, in 1996. Since then, more than 100 families with FTDP‐17 have been described throughout the world, including 18 families identified in Japan.
openaire +2 more sources
New classification of tauopathies
Revue Neurologique, 2018Tauopathies are a group of neurodegenerative diseases characterized by pathological intracellular deposits of the protein tau. Isoform composition, morphology and anatomical distribution of cellular tau-immunoreactivities are defining distinct tauopathies as molecular pathological disease entities.
Höglinger, G. U. +2 more
openaire +3 more sources
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
Nature Reviews Neurology, 2021Maria Stamelou +2 more
exaly
A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies
Signal Transduction and Targeted Therapy, 2021Jie Zheng, Yang Gao
exaly
Structure-based classification of tauopathies
Nature, 2021Yang Shi, Wenjuan Zhang, Benjamin Falcon
exaly
TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease
Science, 2023+2 more
exaly